SCHEMBL25487682

SCHEMBL25487682

C=Cc1cc(-c2ccccc2)nnc1NC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.42
TRIM58 Q8NG06 1/20 0.41
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACHE P22303 2/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 1/20 0.36
ADRB2 P07550 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14944044 0.75 TDP1 (0.46) TDP1SMARCA2SMARCA4PBRM1KDM4E
SCHEMBL20829977 0.68 ACVR2A (0.33) TRIM58ALDH1A1
SCHEMBL11888348 0.68 RAB9A (0.43) TDP1SMARCA2SMARCA4PBRM1KDM4E
SCHEMBL25711816 0.67 NCF1 (0.43) TDP1TRIM58KDM4EALDH1A1GAA
SCHEMBL23205340 0.65 RAB9A (0.52) TDP1SMARCA2SMARCA4PBRM1KDM4E
SCHEMBL21537838 0.65 MKNK2 (0.40) TDP1TRIM58KDM4EALDH1A1SMN1; SMN2
SCHEMBL1752808 0.65 ACHE (0.51) TDP1SMARCA2SMARCA4PBRM1KDM4E
SCHEMBL1752972 0.63 ACHE (0.50) TDP1SMARCA2SMARCA4PBRM1KDM4E
SCHEMBL1752857 0.63 ACHE (0.68) TDP1ACHELMNACYP1A2CYP3A4
SCHEMBL21284326 0.62 KDM4E (0.36) TRIM58KDM4EALDH1A1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 TDP1 1914/4885TRIM58 281/4885SMARCA2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.